Latest Clinical & Research News
Specialty: Heart & Vascular
All patients who undergo a cardiac procedure at the Aortic Disease Center are placed on a list. After discharge, these patients are systematically followed via a robust post-operative tracking system. Issues that crop up are spotted fast.
Read More
Catheter ablation has become an important therapy for patients with ventricular tachycardia (VT). However, it has been a challenge to access arrhythmia sources deep within the heart muscle with the use of conventional approaches.
Read More
It’s estimated that approximately 168,000 TAVR procedures will be performed annually in the United States. According to Pinak Bipin Shah, MD, most TAVR programs grew quickly after the FDA decreased the risk-level indication, but many programs have plateaued.
Building on pioneering work performed during the first wave of heart-lung transplantation, Brigham and Women’s Hospital has resumed its heart-lung program and is once again performing the rare procedure.
On November 10, 2018, the American Heart Association (AHA) held its annual Scientific Sessions meeting, featuring the latest advances from major cardiovascular trials with the potential to transform clinical practice. Investigators from the Brigham led some of the most highly anticipated trials and presented their results at the conference.
Read More
On October 19th, 2018, the HeartMate 3 Left Ventricular Assist System (LVAD) was approved by the FDA as a destination therapy for patients with advanced heart failure who are not eligible for a heart transplant.
In April 2018, the Brigham and Women’s Hospital (BWH) Heart & Vascular Center became the first in New England to perform their 1,000th transcatheter aortic valve replacement (TAVR) procedure.
The hybrid operating room at the Brigham and Women’s Hospital Heart & Vascular Center now features the state-of-art ARTIS Pheno angiography system. As of March 2018, patients who require hybrid cardiovascular interventions combining intravascular and open surgical procedures are reaping the rewards of this cutting-edge technology.
The history of surgery for valvular heart disease at Brigham and Women’s Hospital (BWH) dates to May 1923 when Elliott Carr Cutler, MD, performed the first ever valve operation in the world. Since then, BWH has been at the forefront of the clinical practice and innovation in the management of valve disease. Read More
A new analysis seeks to answer the question of which patients are likely to gain the greatest cardiovascular benefit when treated with the anti-inflammatory agent canakinumab. At the 2017 American Heart Association Scientific Sessions, Paul M. Ridker, MD, director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, presented a pre-specified analysis on CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) that identifies a simple, clinical method to define patient groups most likely to benefit from long-term canakinumab treatment. The results of this analysis, published simultaneously in The Lancet, could have a major impact not only on patient selection and cost-effectiveness of canakinumab, but also on the future development of anti-inflammatory agents for cardiovascular disease. Read More